E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD) - Stage II or III |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effects of 12 weeks of administration of GW842470 4mg bid or placebo on pulmonary hyperinflation in terms of residual volume measured by plethysmography in patients with COPD |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effects of 12 weeks of administration of GW842470 4mg bid or placebo on pulmonary function as assessed by spirometry and plethysmography in patients with COPD.
To evaluate the systemic anti-inflammatory effect of 12 weeks of administration of GW842470 4mg bid or placebo as represented by the serum concentration of C-reactive protein, fibrinogen and inflammatory biomarkers (multiplex assay) in patients with COPD.
To assess the effects of 12 weeks of administration of GW842470 4mg bid or placebo on symptoms of breathleness, cough and sputum production with questionnaires in patients with COPD
To further assess the safety and tolerability of GW842470 in patients with COPD.
To evaluate the plasma concentration of GW842470 over 0-6 hours at steady state.
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Male or female adults between 40 and 80 years of age (inclusive). Females are eligible if they are of: a) Non childbearing potential b) Child-bearing potential, have a negative pregnancy test at entry, and use adequate contraceptive methods
2. Moderate to severe stable COPD (Stage II or III) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
3. A cigarette smoking history of greater or equal to 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year or the equivalent). Both current smokers and ex-smokers are eligible.
4. A post-bronchodilator FEV1 to FVC ratio (FEV1:FVC) < 0.7.
5. A post-bronchodilator FEV1 greater or equal to 30% and <80% of predicted normal for height, age and sex at Screening. Patients will be assessed 30 minutes after receiving salbutamol 400mcg via MDI with a spacer.
6. Evidence of hyperinflation as assessed by (pre-bronchodilator) thoracic gas volume at functional residual capacity (TGVFRC) measured by plethysmography of >120% of predicted TGVFRC and a residual volume (RV) measured by plethysmography >120% of predicted RV at screening.
|
|
E.4 | Principal exclusion criteria |
1. Women who are pregnant or lactating.
2. Women with a positive pregnancy test at Screening.
3. Patients with asthma as the main component of their obstructive airways disease.
4. Patients with poorly controlled COPD, defined as the occurrence of any of the following in the 6 weeks prior to Screening; acute worsening of COPD that was managed by the patient at home by self-treatment with corticosteroids or antibiotics, or that required treatment prescribed by a physician.
5. Patients who have been hospitalized for an exacerbation of COPD in the 6 weeks prior to Screening.
6. Patients with active tuberculosis, lung cancer, or clinically overt bronchiectasis or any other condition known to be associated with inflammation (sarcoidosis and arthritis)
7. Patients with clinically significant cardiovascular, neurological, renal, endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.
8. Patients with clinically significant gastrointestinal or hepatic abnormalities.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in residual volume (RV) measured by plethysmography at Week 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |